title: Intramuscular neridronate in patients with rheumatoid arthritis using corticosteroids: evaluation of treatment adherence in a randomized, open-label comparison with other bisphosphonates.
abstract: OBJECTIVE
  Oral bisphosphonates have been used successfully in patients with rheumatoid arthritis (RA), but their use for the treatment of corticosteroid induced osteoporosis may be limited by poor compliance. Neridronate, an intramuscular and intravenous aminobisphosphonate approved for the treatment of osteogenesis imperfecta and Paget's disease, is also effective in postmenopausal osteoporosis. The aim of this study was to compare the adherence of intramuscular neridronate versus oral alendronate or risedronate in patients with RA with corticosteroid-induced osteopenia.
  
  
  METHODS
  This randomised, open label, parallel-group, single centre study enrolled post-menopausal women (50-70 years), with RA and osteopenia (T-score &gt;-2.5) who were receiving stable dose of methylprednisolone 5 mg or equivalent within the previous 3 months, and expected to continue therapy for at least 12 months. Patients were treated with intramuscular neridronate 25 mg administered once a month, or oral alendronate 70 mg or oral risedronate 35 mg both administered once-weekly, for 12 months. The main outcome measure was adherence to treatment over 1 year, assessed using the Morisky Medication Adherence Scale 4-item (MMAS-4; adherence defined as patients with MMAS-4 score ≥3).
  
  
  RESULTS
  Of 87 women (mean age 61.5 ± 9.2 years) enrolled, 30 were randomized to neridronate, 27 to alendronate and 30 to risedronate therapy. Adherence rates after 12 months were significantly higher with neridronate than with alendronate or risedronate (76.7% vs 47.8% and 48.0%; p&lt;0.05 for both versus neridronate). After 12 months, lumbar and femoral neck BMD and DAS28 were significantly improved in all groups compared with baseline (p&lt;0.05) with no significant difference between the three treatment groups.
  
  
  CONCLUSIONS
  Neridronate is associated with significantly improved adherence to therapy compared with alendronate and risedronate, and improves BMD and disease activity in postmenopausal women with RA and osteopenia. Intramuscular monthly neridronate represents a convenient treatment option for patients with RA using corticosteroids.
authors.affiliation: . mamuratore@libero.it.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Muratore
authors.forename: Eugenio
authors.initials: E
authors.lastname: Quarta
authors.forename: Laura
authors.initials: L
authors.lastname: Quarta
mesh_terms: D000305:Adrenal Cortex Hormones; D019386:Alendronate; D001172:Arthritis, Rheumatoid; D015519:Bone Density / Q000187:drug effects; D004164:Diphosphonates; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D004164:Diphosphonates; D019386:Alendronate